Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Re: VRTX CC from EASL

After all the buildup, EASL concludes not with a bang but a whimper. VRTX will collect more data from the PROVE-n trials during the next few months and talk to the FDA during the summer about how to design phase-3. Investors probably won’t hear anything of great consequence until AASLD.

One canard can now be put to rest, however: the notion, once popular among sell-side analysts, that VRTX could obtain accelerated approval for VX-950 based on only the phase-2 program.